Zacks Investment Research
01 Jul 2026, 22:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Viking Therapeutics (VKTX) is currently assigned a Zacks Rank #4 (Sell). — A 'Sell' rating from a quantitative model used by investors typically suggests bearish near-term sentiment and downward price pressure.
-0.60Viking Therapeutics is forecasted to report a quarterly EPS of -$1.21, a 108.62% decrease from the prior year's corresponding quarter. — Significant deterioration in earnings performance usually triggers negative investor reactions.
-0.50The Medical - Biomedical and Genetics industry is ranked in the bottom 37% of all industries monitored by Zacks. — Weak industry-wide rankings indicate systemic headwinds for companies within this specific sector.
-0.30Continue reading
6 related stories
Search tags
VKTX shares gained 33.19% over the previous month, outperforming both the Medical sector and the S&P 500. — Strong recent momentum suggests positive sentiment, though it may be offset by the 'Sell' rank and poor earnings forecasts.
Which stocks this story touches
The company is rated as a Zacks Rank #4 (Sell) and is forecasting a significant downward movement in EPS.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
